Roche (Nutley, NJ) and Glaxo-SmithKline (Research Triangle Park, NC) recently received FDA approval for Boniva Injectionthe first intravenous (IV) medication indicated for the treatment of postmenopausal osteoporosis. The product is a member of the bisphosphonate class, which is the most frequently prescribed medicine for osteoporosis. Boniva Injection, administered as a 15-to 30-second IV injection, will provide an alternative for patients who have difficulty with oral bisphosphonate dosing requirements. Furthermore, because the product will be administered once every 3 months by health care professionals, clinicians will have a greater awareness of patient compliance with therapy. Boniva Injection 3 mg/3 mL will be available in boxes containing one single- use, clear glass prefilled syringe, along with 1 needle and an alcohol swab. For more information, visit www.gsk.com or www.rocheusa.com.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs